IFG Advisory LLC boosted its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 786.8% during the 3rd quarter, HoldingsChannel reports. The fund owned 12,637 shares of the biotechnology company’s stock after purchasing an additional 11,212 shares during the period. IFG Advisory LLC’s holdings in Biogen were worth $2,854,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Phoenix Financial Ltd. increased its position in shares of Biogen by 23.1% during the 3rd quarter. Phoenix Financial Ltd. now owns 1,793 shares of the biotechnology company’s stock valued at $405,000 after purchasing an additional 336 shares during the last quarter. Danske Bank A S raised its holdings in Biogen by 1,955.2% during the 3rd quarter. Danske Bank A S now owns 1,363,909 shares of the biotechnology company’s stock valued at $308,080,000 after buying an additional 1,297,544 shares during the period. Dogwood Wealth Management LLC lifted its position in Biogen by 47,400.0% in the third quarter. Dogwood Wealth Management LLC now owns 950 shares of the biotechnology company’s stock worth $215,000 after buying an additional 948 shares during the last quarter. Financial Freedom LLC purchased a new position in Biogen during the third quarter worth $34,000. Finally, Moors & Cabot Inc. boosted its stake in Biogen by 4.3% during the third quarter. Moors & Cabot Inc. now owns 1,729 shares of the biotechnology company’s stock worth $391,000 after buying an additional 71 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on BIIB. Weiss Ratings cut shares of Biogen from a “hold (c)” rating to a “hold (c-)” rating in a research report on Thursday, October 29th. Canaccord Genuity Group increased their target price on shares of Biogen from $248.00 to $272.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. Needham & Company LLC raised their target price on shares of Biogen from $256.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. Citigroup reaffirmed a “neutral” rating on shares of Biogen in a research note on Wednesday, October 28th. Finally, Truist Financial reiterated a “buy” rating and set a $260.00 price target (up from $235.00) on shares of Biogen in a report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $254.41.
View Our Latest Report on BIIB
Biogen Price Performance
Shares of BIIB stock opened at $253.40 on Monday. Biogen Inc. has a 52-week low of $160.36 and a 52-week high of $261.00. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.37 and a current ratio of 1.95. The firm has a market capitalization of $37.46 billion, a P/E ratio of 108.29, a P/E/G ratio of 2.87 and a beta of 0.10. The stock has a 50 day moving average price of $233.35 and a 200 day moving average price of $205.04.
Biogen (NASDAQ:BIIB – Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.63. The company had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.63 billion. Biogen had a return on equity of 9.38% and a net margin of 3.37%. Biogen’s revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.81 EPS. As a group, sell-side analysts predict that Biogen Inc. will post 12.46 earnings per share for the current year.
Biogen Profile
Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.
Featured Articles
- Five stocks we like better than Biogen
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
